On August, 28, 2024, Aimed Alliance received an interim response from the Food and Drug Administration regarding its Citizen Petition on alternative funding programs and their use of international importation. Given the nuances of the issue, the FDA stated it was “unable to reach a decision on your petition because it raises complex issues requiring extensive review and analysis by Agency officials. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as we have reached a decision on your request.”
Aimed Alliance applauds the FDA for recognizing the complexity and risks of international importation. We continue to urge FDA to swiftly address this issue and ensure consumers cannot be mandated by their employers to import their medications from outside the United States. Read FDA’s interim letter.
Last Updated on August 28, 2024 by Aimed Alliance
